View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
 PRESS RELEASE

Apellis and Sobi Announce EMPAVELI® (pegcetacoplan) Showed Sustained E...

Apellis and Sobi Announce EMPAVELI® (pegcetacoplan) Showed Sustained Efficacy at One Year in Phase 3 Study for C3G and Primary IC-MPGN Robust proteinuria reduction and stable kidney function were maintained across a broad population of patients No new safety signals were observedNew data presented at late-breaking session at the European Renal Association CongressMarketing applications for EMPAVELI are under review with the FDA and EMA WALTHAM, Mass. and STOCKHOLM, June 06, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Sobi® (STO:SOBI) today presented new dat...

 PRESS RELEASE

Apellis Pharmaceuticals to Present at the Goldman Sachs 46th Annual Gl...

Apellis Pharmaceuticals to Present at the Goldman Sachs 46th Annual Global Healthcare Conference WALTHAM, Mass., June 04, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will present at the Goldman Sachs 46th Annual Global Healthcare Conference on Wednesday, June 11, 2025 at 10:40 a.m. ET. The live conference webcast will be posted on the “Events and Presentations” page of the “Investors and Media” section of the company’s . A replay of the webcast will be available for approximately 90 days following the event. About ApellisApellis...

Wedbush Research
  • Wedbush Research
UBI UBISOFT ENTERTAINMENT SA
XNCR XENCOR INC.
XENE XENON PHARMACEUTICALS INC
VYGR VOYAGER THERAPEUTICS INC.
TTWO TAKE-TWO INTERACTIVE SOFTWARE INC.
RARE ULTRAGENYX PHARMACEUTICAL INC.
NVCR NOVOCURE LTD.
NBIX NEUROCRINE BIOSCIENCES INC.
KURA KURA ONCOLOGY INC.
GME GAMESTOP CORP. CLASS A
GERN GERON CORP.
FATE FATE THERAPEUTICS INC
CTMX CYTOMX THERAPEUTICS INC.
BPMC BLUEPRINT MEDICINES CORP.
BMRN BIOMARIN PHARMACEUTICAL INC.
BIIB BIOGEN INC.
ASND ASCENDIS PHARMA A/S SPONSORED ADR
ARDX ARDELYX INC
CDR CD PROJEKT S.A.
FRX_CN FENNEC PHARMACEUTICALS
7974 NINTENDO CO. LTD.
BLDR BUILDERS FIRSTSOURCE INC.
EA ELECTRONIC ARTS INC.
ANAB ANAPTYSBIO INC.
ARGX ARGENX ADS
MRSN MERSANA THERAPEUTICS
ISR ISORAY
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
APLS APELLIS PHARMACEUTICALS
DNLI DENALI THERAPEUTICS INC
RCUS ARCUS BIOSCIENCES
SRRK SCHOLAR ROCK HOLDING CORPORATION
KNSA KINIKSA PHARMACEUTICALS
REPL REPLIMUNE GROUP
ARVN ARVINAS HOLDING
YMAB Y-MABS THERAPEUTICS
STRO SUTRO BIOPHARMA
PINS PINTEREST INC. CLASS A
STOK STOKE THERAPEUTICS
IGMS IGM BIOSCIENCES
SWTX SPRINGWORKS THERAPEUTICS
APRE APREA THERAPEUTICS
IDYA IDEAYA BIOSCIENCES
RVMD REVOLUTION MEDICINES
PASG PASSAGE BIO
BDTX BLACK DIAMOND THERAPEUTICS
ACET ADICET BIO INC
KROS KEROS THERAPEUTICS
ITOS ITEOS THERAPEUTICS
ZNTL ZENTALIS PHARMACEUTICALS
LRMR LARIMAR THERAPEUTICS INC
PRAX PRAXIS PRECISION MEDICINES
U UNITY SOFTWARE
TVTX TRAVERE THERAPEUTICS INC
UFPI UFP INDUSTRIES INC.
VRDN VIRIDIAN THERAPEUTICS INC
IMNM IMMUNOME
PLTK PLAYTIKA HOLDING
NUVB NUVATION BIO INC (A)
RBLX ROBLOX
CGEM CULLINAN ONCOLOGY INC
DAWN DAY ONE BIOPHARMACEUTICALS INC
ELEV ELEVATION ONCOLOGY
TCRX TSCAN THERAPEUTICS INC
APP APPLOVIN CORP
ATXS ASTRIA THERAPEUTICS INC
GMTX GEMINI THERAPEUTICS INC
VIGL VIGIL NEUROSCIENCE INC
TYRA TYRA BIOSCIENCES INC
EWTX EDGEWISE THERAPEUTICS INC
NUVL NUVALENT INC
ARTV ARTIVA BIOTHERAPEUTICS INC
DDI DOUBLEDOWN INTERACTIVE CO LTD
APGE APOGEE THERAPEUTICS INC
SKLZ SKILLZ INC
EMBRAC B EMBRACER GROUP AB
BCAX BICARA THERAPEUTICS INC.
David Nierengarten ... (+8)
  • David Nierengarten
  • Dennis Pak
  • Dylan Shindler
  • Laura Chico
  • Martin Fan
  • Ritika Das
  • Robert Driscoll
  • Yun Zhong
 PRESS RELEASE

Seres Therapeutics Presents Expanded SER-155 Exploratory Biomarker Dat...

Seres Therapeutics Presents Expanded SER-155 Exploratory Biomarker Data at 2025 ASCO Annual Meeting Results highlight potential role of SER-155 in promoting peripheral T-cell recovery and immune reconstitution to support favorable outcomes post allogeneic hematopoietic stem cell transplant (allo-HSCT) CAMBRIDGE, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB) (Seres or the Company), a leading live biotherapeutics company, today announced the Company will be presenting new exploratory biomarker data from its SER-155 Phase 1b study in a poster session at th...

International Flavors & Fragrances Inc: 1 director

A director at International Flavors & Fragrances Inc bought 4,500 shares at 76.053USD and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over th...

Snap Inc: 3 directors

Three Directors at Snap Inc sold after exercising options/sold 243,139 shares at between 8.542USD and 8.595USD. The significance rating of the trade was 75/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the compa...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: May 17, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Dan Salmon
  • Dan Salmon

US Internet 1Q25 Update Better than feared, but still choppy ahead

We update models for our US Internet coverage following earnings, with estimates and target valuations generally higher.

Wedbush Research
  • Wedbush Research
DPZ DOMINO'S PIZZA INC.
SHAK SHAKE SHACK INC. CLASS A
DEI DOUGLAS EMMETT INC
HPP HUDSON PACIFIC PROPERTIES INC.
XENE XENON PHARMACEUTICALS INC
WING WINGSTOP INC.
WEN WENDY'S COMPANY
WDC WESTERN DIGITAL CORPORATION
VYGR VOYAGER THERAPEUTICS INC.
TXRH TEXAS ROADHOUSE INC.
TSLA TESLA INC
TRNO TERRENO REALTY CORPORATION
STKS ONE GROUP HOSPITALITY
STAG STAG INDUSTRIAL INC.
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
SBUX STARBUCKS CORPORATION
PZZA PAPA JOHN'S INTERNATIONAL INC.
PEGA PEGASYSTEMS INC.
OFC CORPORATE OFFICE PROPERTIES TRUST
MCD MCDONALD'S CORPORATION
JACK JACK IN THE BOX INC.
IMAX IMAX CORPORATION
EGP EASTGROUP PROPERTIES INC.
EAT BRINKER INTERNATIONAL INC.
DIN DINE BRANDS GLOBAL INC.
DENN DENNY'S CORPORATION
CTMX CYTOMX THERAPEUTICS INC.
CHKP CHECK POINT SOFTWARE TECHNOLOGIES LTD.
CAKE CHEESECAKE FACTORY INCORPORATED
BXP BOSTON PROPERTIES INC.
BIIB BIOGEN INC.
ARDX ARDELYX INC
BJRI BJ'S RESTAURANTS INC.
FRX_CN FENNEC PHARMACEUTICALS
CMG CHIPOTLE MEXICAN GRILL INC.
DRI DARDEN RESTAURANTS INC.
WVE WAVE LIFE SCIENCES
PLYM PLYMOUTH INDUSTRIAL REIT INC.
MRSN MERSANA THERAPEUTICS
ISR ISORAY
AMZN AMAZON.COM INC.
AAPL APPLE INC.
RCKT ROCKET PHARMACEUTICALS
MSFT MICROSOFT CORPORATION
IBM INTERNATIONAL BUSINESS MACHINES CORPORATION
APLS APELLIS PHARMACEUTICALS
SRRK SCHOLAR ROCK HOLDING CORPORATION
YMAB Y-MABS THERAPEUTICS
TVTX TRAVERE THERAPEUTICS INC
PLTK PLAYTIKA HOLDING
RBLX ROBLOX
TNGX TANGO THERAPEUTICS
VERA INC
BROS VERA THERAPEUTICS INC
STRW DUTCH BROS INC
CAVA STRAWBERRY FIELDS REIT INC.
JBIO CAVA GROUP INC
JADE BIOSCIENCES
INC.
Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: May 10, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

DHIL DIAMOND HILL INVESTMENT GROUP
RGR STURM RUGER & COMPANY INC.
PEB PEBBLEBROOK HOTEL TRUST
PCAR PACCAR INC
NG. NOVAGOLD RESOURCES INC.
NBTB NBT BANCORP INC.
MTX MINERALS TECHNOLOGIES INC.
MTDR MATADOR RESOURCES COMPANY
MMLP MARTIN MIDSTREAM PARTNERS L.P.
IFF INTERNATIONAL FLAVORS & FRAGRANCES INC.
HUN HUNTSMAN CORPORATION
HL HECLA MINING COMPANY
CHDN CHURCHILL DOWNS INCORPORATED
CFFN CAPITOL FEDERAL FINANCIAL INC.
CBRL CRACKER BARREL OLD COUNTRY STORE INC.
BIIB BIOGEN INC.
APLE APPLE HOSPITALITY REIT INC
OFIX ORTHOFIX INTERNATIONAL N.V.
CAT CATERPILLAR INC.
ARCB ARCBEST CORPORATION
HTLD HEARTLAND EXPRESS INC.
USAC USA COMPRESSION PARTNERS LP
NHC NATIONAL HEALTHCARE CORP.
JELD JELD-WEN HOLDING INC.
FCNCA FIRST CITIZENS BANCSHARES INC. CLASS A
MAV PIONEER MUNICIPAL HIGH INCOME ADVANTAGE TRUST
OCSL OAKTREE SPECIALTY LENDING CORPORATION
SNBR SLEEP NUMBER CORPORATION
RCII RENT-A-CENTER INC
A2H9KJ NEO PERFORMANCE MATERIAL
KKR KKR & CO. INC.
REZI RESIDEO TECHNOLOGIES
TROX INC.
UTGN TRONOX HOLDINGS PLC
CCO UTG
AVTR CLEAR CHANNEL OUTDOOR HOLDINGS INC
GCI AVANTOR
DCTH INC.
ONEW GANNETT CO. INC.
DLHC DELCATH SYSTEMS
UTZ ONEWATER MARINE
OGN DALEIGH HOLDINGS CORP
NVCT UTZ BRANDS INC (A)
PRAA ORGANON & CO
VSTS_w NUVECTIS PHARMA INC
BNL PORTFOLIO RECOVERY ASSOCIATES
DMA INC.
SUNS VESTIS CORPORATION
GF BROADSTONE NET LEASE INC
FG DESTRA MULTI ALTERNATIVE FUND
EU SUNRISE REALTY TRUST
ECF THE NEW GERMANY FUND
HCWB INC.
F AND G ANNUITIES AND LIFE
INC.
WISDOMTREE EURO DEBT FUND
ELLSWORTH FUND LTD
HCW BIOLOGICS INC
Dylan Shindler ... (+2)
  • Dylan Shindler
  • Laura Chico
 PRESS RELEASE

Seres Therapeutics Reports First Quarter 2025 Financial Results and Pr...

Seres Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates In line with recent FDA feedback, Seres expects to submit a Phase 2 study protocol to FDA in the coming weeks for SER-155 for the prevention of bloodstream infections (BSIs) in adults undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT) for the treatment of hematological malignancies SER-155 Phase 1b placebo-controlled study exploratory translational biomarker data reinforce intended mechanisms of action, consistent with clinical results that showed a significant reduction (77% rel...

 PRESS RELEASE

Apellis Pharmaceuticals Reports First Quarter 2025 Financial Results

Apellis Pharmaceuticals Reports First Quarter 2025 Financial Results Generated $166.8 million in 1Q 2025 revenues, including $149.9 million in U.S. net product salesSYFOVRE® (pegcetacoplan injection) injection demand grew 4% quarter-over-quarter, with U.S. net product revenue of $130.2 million Increase in demand offset by inventory dynamics and funding shortages at co-pay assistance programs Received U.S. FDA filing acceptance of supplemental new drug application (sNDA) with Priority Review designation for EMPAVELI for treatment of C3G and primary IC-MPGNOn track to initiate two pivotal tri...

Wedbush Research
  • Wedbush Research
 PRESS RELEASE

Apellis Pharmaceuticals to Present at Upcoming Investor Conferences

Apellis Pharmaceuticals to Present at Upcoming Investor Conferences WALTHAM, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will participate in the following May investor conferences: BofA Securities 2025 Healthcare Conference: Fireside chat on Tuesday, May 13, 2025 at 8:40 a.m. PTStifel 2025 Virtual Ophthalmology Forum: Fireside chat on Tuesday, May 27, 2025 at 2:30 p.m. ET The live conference webcasts will be posted on the “Events and Presentations” page of the “Investors and Media” section of the company’s . A rep...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch